Coherus BioSciences Announces New Employment Inducement Grants
February 17 2017 - 8:30AM
Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that
effective February 16, 2016, the compensation committee of the
company’s board of directors granted 6 new employees options to
purchase an aggregate of 155,000 shares of the company’s common
stock with a per share exercise price of $23.00, the closing
trading price on the grant date. In addition, options to
purchase 45,000 shares of common stock were granted to a Vice
President, Regulatory Affairs new hire under the same terms.
Finally, a Senior Vice President, Clinical Development new hire was
granted options to purchase 125,000 shares of common stock under
the same terms as well as restricted stock units underlying 12,000
shares of common stock. The stock options and restricted stock
units were granted pursuant to the Coherus BioSciences, Inc. 2016
Employment Commencement Incentive Plan, which was approved by the
company’s board of directors in June 2016 under Rule 5635(c)(4) of
the Nasdaq Global Select Market for equity grants to induce new
employees to enter into employment with the company.
About Coherus BioSciences, Inc. Coherus is a
leading pure-play, global biosimilar company that develops and
commercializes high-quality therapeutics for major regulated
markets. Biosimilars are intended for use in place of existing,
branded biologics to treat a range of chronic and often
life-threatening diseases, with the potential to reduce costs and
expand patient access. Composed of a team of proven industry
veterans with world-class expertise in process science, analytical
characterization, protein production, sales & marketing and
clinical-regulatory development, Coherus is positioned as a leader
in the global biosimilar marketplace. Coherus is advancing three
late-stage clinical products towards commercialization, CHS-1701
(pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and
CHS-1420 (adalimumab biosimilar), as well as developing a robust
pipeline of future products in four therapeutic areas, oncology,
immunology (anti-TNF), ophthalmology and multiple sclerosis. For
additional information, please visit www.coherus.com.
CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
pobrien@coherus.com
+1 (650) 649-3527
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2023 to Apr 2024